Androgen receptor expression reduces stemness characteristics of prostate cancer cells (PC3) by repression of CD44 and SOX2

Deepa Srinivasan | Linda Senbanjo | Sunipa Majumdar | Renty B. Franklin | Meenakshi A. Chellaiah

Department of Oncology and Diagnostic Sciences, University of Maryland Dental School, Baltimore, Maryland

Correspondence
Meenakshi A. Chellaiah, PhD, Department of Oncology and Diagnostic Sciences, University of Maryland Dental School, 7th Floor (South), Rm7207, 650W Baltimore St, Baltimore, MD 21201. Email: mchellaiah@umaryland.edu

Funding information
National Institute of Arthritis and Musculoskeletal and Skin Diseases, Grant/Award Number: R01AR066044

Abstract
Studies have shown that a subgroup of tumor cells possess stemness characteristics having self-renewal capacity and the ability to form new tumors. We sought to identify the plausible stemness factor that determines the “molecular signature” of prostate cancer (PCa) cells derived from different metastases (PC3, PCa2b, LNCaP, and DU145) and whether androgen receptor (AR) influences the maintenance of stemness features. Here we show sex-determining region Y (SRY)-box 2 (SOX2) as a putative stem cell marker in PC3 PCa cells and not in DU145, PCa2b, or LNCaP cells. PCa2b and PC3 cells were derived from bone metastases. PCa2b cells which are positive for the AR failed to demonstrate the expression of either cluster of differentiation 44 (CD44) or SOX2. Knockdown (KD) of AR in these cells did not affect the expression of either CD44 or SOX2. Conversely, PC3 cells, which are negative for AR, expressed both CD44 and SOX2. However, the expression of AR downregulated the expression of both CD44 and SOX2 in PC3 cells. CD44 regulates SOX2 expression as KD of CD44 and reduces SOX2 levels considerably. SOX2 KD attenuated not only the expression of SNAIL and SLUG but also the migration and tumorsphere formation in PC3 cells. Collectively, our findings underscore a novel role of CD44 signaling in the maintenance of stemness and progression of cancer through SOX2 in AR-independent PC3 cells. SOX2 has a role in the regulation of expression of SNAIL and SLUG. SOX2 could be a potential therapeutic target to thwart the progression of SOX2-positive cancer cells or recurrence of androgen-independent PCa.

KEYWORDS
androgen receptor, cancer stem cells, cluster of differentiation 44, prostate cancer, sex-determining region Y (SRY)-box 2

Abbreviations: AR, androgen receptor; CD44, cluster of differentiation 44; CSC, cancer stem cells; EMT, epithelial-mesenchymal transition; IB, immunoblot; OCT4, octamer-binding transcription factor 4; PCa, prostate cancer; RT-PCR, reverse-transcription polymerase chain reaction; siRNA, small interfering RNA; SOX2, sex-determining region Y (SRY)-Box 2.

D. Srinivasan and L. Senbanjo have contributed equally to this work.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2018 The Authors. Journal of Cellular Biochemistry Published by Wiley Periodicals, Inc.
Prostate cancer (PCa) is the second leading cause of cancer-related death among men in the United States, behind only lung cancer.1 It is a disease of extensive metastases with secondary lesions commonly occurring in lymph nodes, brain, bones, and sometimes in visceral organs such as the liver and lungs.2,3 While androgen-deprivation therapy targeted toward androgen receptor (AR) signaling is widely used for advanced PCa, this therapeutic strategy has been marred by major clinical limitations. Patients who initially respond to androgen-deprivation therapy progress to develop an androgen-independent stage or castration-resistant PCa, which is unresponsive to hormone deprivation resulting in relapse with a more aggressive disease.4,5

Emerging evidence from various human tumors indicates the presence of heterogeneous populations of cells within tumor bulk that comprise tumor cells and a small subpopulation of somatic cells with stem-like properties, termed as cancer stem cells (CSCs).6,7 CSCs are considered to be major drivers of treatment failure and tumor recurrence due to their ability to resist and survive through conventional therapies and their dynamic self-renewal capabilities. Recent reports indicate the potential expansion of CSCs triggered by selection pressures imposed by androgen-deprivation therapy in PCa.8-10 Therefore, we aim to understand the association between the CSC phenotype and AR. One of the potential mechanistic explanations put forward involves the ability of the AR to regulate sex-determining region Y (SRY)-box 2 (SOX2), octamer-binding transcription factor 4 (OCT4), and NANOG transcription factors. These factors constitute the core embryonic transcription factor machinery.11-13 Pivotal work by Takahashi et al14 showed that SOX2 and OCT4, together with KLF4 and c-MYC could reprogram human somatic cells to pluripotent stem cells.15 The ability of these factors to confer stemness would have major clinical implications, whereby their re-expression in adult CSCs could result in a more aggressive tumor phenotype. Dysregulated expression of these factors has been widely associated with enhanced tumorigenicity.11,16,17 For instance, SOX2 overexpression was found to promote extensive metastasis of breast and PCa cells through epithelial-mesenchymal transition (EMT).18-20

EMT is one of the key steps in the metastatic process whereby epithelial cells lose cell-cell contact and polarity, becoming more migratory and invasive. EMT demonstrates the expression of transcriptional factors (eg, SNAIL and SLUG), downregulation of the epithelial marker (eg, E-cadherin), and upregulation of mesenchymal markers (eg, N-cadherin, vimentin, and fibronectin).21-23 Cancer cells that undergo EMT are thought to acquire CSC-like features, making them more compatible for metastasis.9,10 Studies in pancreatic ductal adenocarcinoma and colorectal cancer have interrelated CSC phenotype and EMT, and have implicated the core embryonic transcription factors to be critical in mediating their shared properties.24,25 Interestingly, in PCa the androgen deprivation therapeutic approach has been shown to promote the acquisition of EMT phenotype.26 Because androgen deprivation therapy also results in the expansion of CSCs, these findings suggest that a potential AR-CSC-EMT axis may be responsible for advanced PCa progression.

Cluster of differentiation 44 (CD44) is a transmembrane receptor that is known to have significant roles in cell-cell interactions, cell adhesion, and migration.27 CD44 signaling via extracellular matrix ligands such as hyaluronic acid, osteopontin, collagens, and matrix metalloproteinases has been shown to increase the metastatic potential of cancer cells.28 Moreover, CD44 has also been recognized as a marker of CSCs in breast and PCa.28,29

Our current study aims to characterize the expression patterns of stemness factors SOX2, OCT4, and NANOG in PCa cell lines derived from different metastases, to identify the key stemness factor that determines the “molecular signature” of potential PCa stem cells. Additionally, we also wanted to examine whether AR has a role in the maintenance of stemness characteristics of these PCa cells. Strikingly, we show here, (a) the antagonistic effect of AR in the expression of SOX2 and CD44; and (b) the vital role of CD44-SOX2 signaling axis in the expression of SNAIL and SLUG, as well as cell migration.

2  MATERIALS AND METHODS

2.1  Cell culture

PC3 cell line stably expressing AR (PC3/AR+) was generated in Dr Renty B. Franklin’s Laboratory (University of Maryland Dental School, Baltimore, MD). Stable PC3 cell line knockdown (KD) of CD44 (PC3/CD44−) was generated as described previously.30 PC3, LNCaP, DU145, PC3/AR+, and PC3/CD44− cells were cultured in Roswell Park Memorial Institute (RPMI)-1640 medium containing 10% fetal bovine serum (FBS), as previously described.3,30 Also, normal prostatic epithelial cells (HPR1), which are used as controls were cultured in keratinocyte medium supplemented with epidermal growth factor (EGF) (2.5 mg/500 mL) and bovine pituitary extracts (25 mg/500 mL) (Gibco, Life Technologies,
Bethesda, MD).\textsuperscript{31} MDA PCa2b cells (referred to as PCa2b) were cultured in BRFF-HPC1 (AthenaES, Baltimore, MD) medium containing only 10% FBS, slight modifications from previously described specifications.\textsuperscript{32} The FBS used in PCa2b culture media is nonheat inactivated (16000036; Gibco, Life Technologies). All cell culture media were supplemented with penicillin and streptomycin (1%) and the cells were maintained at 37°C in a humidified incubator with 5% CO₂.

### 2.2 Reverse-transcription polymerase chain reaction

Reverse-transcription polymerase chain reaction (RT-PCR) was done as described previously.\textsuperscript{33} Briefly, total RNA was extracted from different cell lines using the RNeasy Midi kit (Qiagen, Valencia, CA). Complementary DNA (cDNA) was synthesized from RNA using Super-Script III First-Strand Synthesis System (Invitrogen, Carlsbad, CA), with 5 μg of total RNA. RT-PCR for NANOG, OCT4, SOX2, and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was done with the cDNA generated, JumpStart REDTaq ReadyMix PCR Reaction Mix (Sigma-Aldrich, St Louis, MO), and the appropriate primer sets. GAPDH level was used for normalization. Samples were electrophoresed on 1.5% agarose gel and stained with GelGreen (Biotium Inc, Hayward, CA). The forward (F) and reverse (R) primers used for the genes are as follows:

- **NANOG**: F: 5′-ACCTATGCGCTGTGATTTGTG-3′, R: 5′-AAGTGAAGGCTGGGTAAGGTA GG-3′;
- **OCT4**: F: 5′-GAGAATTGTTCTGCAGTGC-3′, R: 5′-GGTCCCAATTCCTTCTCGA G-3′;
- **SOX2**: F: 5′-ATGGGTTCGGTGGTCAAGT C-3′, R: 5′-GGATGGTG TTCTC-3′;
- **GAPDH**: F: 5′-ACCAAGTGATGCACCCCT-3′, R: 5′-GATGCAGGGATGTATGTC-3′.

### 2.3 RNA extraction and quantitative real-time PCR

Total RNA was extracted from PC3 cells with SOX2 KD and control cells using RNeasy Midi Kit (Qiagen). cDNA was synthesized from RNA using Super-Script III First-Strand Synthesis System (Invitrogen), with 3 μg of total RNA. The cDNA generated was used for standard real-time PCR analysis to quantitate levels of SOX2, OCT4, NANOG, CD44, and GAPDH transcripts using custom primers and SYBR Universal Master Mix (Applied Biosystems, Foster City, CA). Each reaction was performed in triplicates in 20 μL volume in 96-well plates in an ABI 7000HT thermocycler (Thermo Fisher Scientific, Waltham, MA) (2 minutes at 50°C, 10 minutes at 95°C, 40 cycles for 15 seconds at 95°C, and 1 minute at 60°C). The gene expression was calculated relative to that of control cells and normalized for GAPDH and measured under the same conditions using the $2^{-ΔΔC_{t}}$ method.\textsuperscript{30,34}

The forward (F) and reverse (R) primers used for the genes are as follows:

- **NANOG**: F: 5′-ATGCGCTACACGGAGACTGT-3′, R: 5′-AAGTGGGTTGGT GCCTTGTG-3′;
- **OCT4**: F: 5′-TGGAGACCGAGTGAGGAGG-3′, R: 5′-GAACCACACTGCGACCACA-3′;
- **SOX2**: F: 5′-AACCACAAAGAGCCACAATCT-3′, R: 5′-CGGGCGGCTATTTATAAATC-3′;
- **CD44F**: 5′-ACCGACAGCAGACAGACAATC-3′, R: 5′-GTGGTCTCCACCTTCTGACT-3′;
- **GAPDH**: F: 5′-TGCACCAACACTGCTTAG-3′, R: 5′-GATGCAGGGATGTATGTC-3′.

### 2.4 Lysis of cells and immunoblotting analysis

Cells were washed three times with cold phosphate-buffered saline (PBS) and lysates were collected using cold radioimmunoprecipitation assay lysis buffer. Lysis buffer was supplemented with ethylenediaminetetraacetic acid (EDTA)-free complete mini protease inhibitor cocktail (1 tablet per 10 mL lysis buffer) immediately before use. After incubating on ice for 15 minutes, lysates were centrifuged for 15 minutes at 18 000 rpm at 4°C. The supernatants were saved and protein concentrations were measured. Protein lysates were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotting (IB) analysis as described previously with slight modification.\textsuperscript{30} Samples were heated at 70°C for 15 minutes, instead of boiling for 5 minutes. SOX2 (3579S-CST), NANOG (3580S-CST), OCT4 (2750S-CST), SNAIL (3879S-CST), SLUG (9585S-CST), CD44 (3570S-CST), E-cadherin (3195S-CST), N-cadherin (14215S-CST), and nucleoporin (2598S-CST) antibodies for IB analysis were purchased from Cell Signaling Technology, Inc (Danvers, MA). AR antibody (SC-7305) was obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Antibody to GAPDH (G9545) was purchased from Sigma-Aldrich. Horseradish peroxidase–conjugated secondary antibodies were obtained from Kirkegaard & Perry Laboratories (Gaithersburg, MD; anti-rabbit) and Santa Cruz Biotechnology (anti-mouse). Protein estimation reagent kit, molecular weight protein standards, and polyacrylamide solutions were purchased from Bio-Rad (Hercules, CA). Polyvinylidene fluoride membrane for IB analysis was obtained from Millipore...
were then rinsed three times in PBS-RT for 5 minutes each, mounted on slides using mounting media containing DAPI, and sealed with nail polish. The slides were viewed and photographed on Zeiss LSM 510 META Confocal Laser Scanning Microscopes (Zeiss, Germany). Images were analyzed with ImageJ software program, scriptable Java app for scientific image processing (Softonic International Ed. Media TIC, Barcelona, Spain).

2.8 | KD of SOX2 in PC3 cells using small interfering RNA

PC3 cells were grown in six-well plates overnight at 37°C, and allowed to reach around 60% confluency. Small interfering RNA (siRNA) designed against SOX2 (GE Healthcare Dharmacon Inc, Lafayette, CO) was transfected into PC3 cells using Lipofectamine 2000 (Thermo Fisher Scientific, Waltham, MA). SMARTpool siRNA represent four pooled SMART-selected siRNA duplexes that target the SOX2 gene. Scrambled nontargeting RNA interference (RNAi) was used as the negative control (Thermo Fisher Scientific Inc, Waltham, MA). SOX2-scrambled RNAi and siRNA were used to a final concentration of 100 nM. Five hours after the KD, the media in the plates were changed to complete RPMI media. Twenty-four hours later, cell lysates were collected, and subjected to SDS-PAGE and IB analysis to confirm the KD.

2.9 | KD of AR in PCA2B cells using siRNA

PCA2b cells were grown in six-well plates overnight at 37°C, and allowed to reach around 60% confluency. Human AR siRNA (Dharmacon, Horizon, Lafayette, CO) was transfected into PCA2b cells using Lipofectamine 2000. Scrambled nontargeting siRNA was used as the negative control (Thermo Fisher Scientific Inc.). AR scrambled RNAi and siRNA were used to a final concentration of 100 nM. Twenty-four hours after the KD, the media in the plates were changed to complete RPMI media. Twenty-four hours later, cell lysates were collected, and subjected to SDS-PAGE and IB analysis to confirm KD and tumorsphere formation assay was performed.

2.10 | Wound closure assay

Uniform vertical streaks were made in the monolayer culture with 200 μL pipette tips. The cells were immediately washed three times with RPMI medium with 10% FBS to remove detached cells. Mitomycin C (10 μg/mL; Sigma-Aldrich) was added to the medium
to inhibit proliferation, so that migration can be effectively followed. Mitomycin C is known to inhibit DNA synthesis using forming covalent crosslinks between complementary strands of DNA. This ultimately prevents separation of complementary strands of DNA, thereby inhibiting DNA replication. Cell migration was monitored for 24 hours, and pictures were taken at 0, 18, and 24 hours time points with a digital SPOT camera attached to an inverted Nikon phase contrast microscope (Nikon Inc., Melville, NY).

For wound closure assay in PC3 cells with KD of SOX2, siRNA KD of SOX2 was first performed on PC3 cells as described above. Twenty-four hours post-KD, the SOX2 siRNA transfected cells and nontargeting control siRNA transfected cells were replated in six-well plates, grown overnight at 37°C, and allowed to reach near-confluent levels. The wound closure assay was then performed as mentioned above. Parallel cultures were used to confirm SOX2 KD as compared with control siRNA-treated cells

2.11 Tumorsphere formation assay

PCa cells that were 80% to 90% confluent were detached with trypsin-EDTA solution. The cells were centrifuged for 3 minutes at 1200 rpm and the supernatant discarded. The cells were then resuspended in a small volume of StemXVivo-Serum-Free Tumorsphere Media (R&D Systems Inc., Minneapolis, MN) (CCM012) containing 2 U/mL heparin (2812; Tocris, Bio-Techne Corporation, Minneapolis, MN) and 0.8 µg/mL hydrocortisone (4093; Tocris). The cells were plated at 0.05 × 10⁶ cells per well in a six-well ultralow adhesion culture plate and cultured at 37°C and 5% CO₂ for 7 days to induce tumorsphere formation as described. After 7 days tumorspheres were imaged using a Cytation 3 Imaging Reader from Biotek (Winooski, VT).

2.12 Statistical analysis

All values presented as mean ± SEM. A value of P less than 0.05 was considered significant. Two-tailed Student t test
determined statistical significance. All of the data were analyzed with GraphPad Prism (GraphPad Software, Inc, La Jolla, CA).

3 | RESULTS

3.1 | PC3 cells demonstrate a marked increase in SOX2 expression at protein and messenger RNA levels as compared with other PCa cell lines

Here, our primary aim is to identify the expression of stemness factors at messenger RNA (mRNA) and protein levels in different PCa cell lines derived from human bone (PC3), brain (DU145), or lymph node (LNCaP) metastases. Normal prostatic epithelial cells (HPR1) were used as controls. IB, RT-PCR, and real-time PCR analysis were used to confirm the expression levels in the indicated cell lines. NANOG expression was more in PC3 and DU145 cells at the protein level (Figure 1A, lanes 2 and 4); however its expression was considerably lower than HPR1 cells (Figure 1A, lane 1). The expression of NANOG at mRNA levels was not significantly different in all the cell lines tested (Figure 1B and 1C). OCT4 is not expressed at the protein levels of all the cell lines tested (Figure 1A) but OCT4 mRNA levels were found to be more in LNCaP cells (Figure 1B, lane 3, and Figure 1C) as compared with PC3 and DU145 cells (Figure 1B, lanes 2 and 4, and Figure 1C). Interestingly, SOX2 expression was more in PC3 cells at the protein (Figure 1A, lane 2) and mRNA levels (Figure 1B, lane 2, and Figure 1C). SOX2 was not expressed in LNCaP and DU145 cells (Figure 1A, lanes 3 and 4). Furthermore, while there was more SOX2 expression at the mRNA level (Figure 1B, lane 1, and Figure 1C), the protein level was considerably lower in HPR1 cells (Figure 1A, lane 1). Since there was an increase in SOX2 in PC3 cells, we determined the expression levels of SOX2 protein in human prostatic TT lysates (Figure 1D, lane 2). SOX2 expression was more in TT lysates than the normal prostatic tissue (NT) lysates (Figure 1D, lane 1), suggesting that expression of SOX2 may have a role in the progression of cancer. However, further analyses are required to determine the expression levels of other stem cell markers in TT lysates. Since advanced PCa is known to metastasize to the bones in almost 85% to 100% of cases, we suggest that increased SOX2 could be a potential candidate to pursue in bone metastatic PC3 cells.

FIGURE 2 Analysis of the localization of SOX2 in prostate cancer cell lines. A, Immunostaining and confocal microscopy analysis of the distribution of SOX2 (green) in PC3, LNCaP, and DU145 cells. DAPI nuclear counterstain (blue) was used to demonstrate the specific localization of SOX2 in the nuclei of PC3 cells. B, Immunoblotting analyses of nuclear lysates from indicated cell lines with a SOX2 antibody validates the immunostaining analysis of the nuclear localization of SOX2 in PC3 cells (lane 1). Nucleoporin immunoblot demonstrates equal loading of nuclear proteins in each lane. The results represent one of the three separate experiments performed with similar results. DAPI, 4’,6-diamidino-2-phenylindole; SOX2, sex-determining region Y (SRY)-box 2.
3.2 | SOX2 localization is more in the nucleus of PC3 cells

Since SOX2 functions as a transcriptional factor, we proceeded to determine its localization by immunostaining and confocal analyses (Figure 2A). We have shown here that the localization of SOX2 was more in the nucleus of PC3 cells. It is nearly undetectable in LNCaP and DU145 cells. IB analysis of nuclear lysates from these cells indeed corroborates this observation (Figure 2B).

3.3 | KD of SOX2 reduces expression of EMT-related factors such as SNAIL and SLUG in PC3 cells

To determine the functional role of SOX2, we used the KD strategy. Here, our goal is to determine the following:

(a) Is there any compensatory mechanism(s) by other stemness factors, (b) Does SOX2 regulate the expression of any EMT markers, and (c) Does it have a role in the migration and tumorsphere formation of PC3 cells. SMARTpool siRNA to SOX2 was used to KD SOX2 expression in PC3 cells and the KD was confirmed by IB and real-time PCR analyses (Figure 3A and 3E).

(1) Other stemness factors do not compensate loss of SOX2. OCT4 is not expressed at the protein level in PC3 cells (Figure 1A, lane 2), and its expression pattern did not change with the introduction of SOX2-scrambled RNAi or siRNA (Figure 3B). Similarly, the expression level of NANOG is not affected in these cells (Figure 3C). At mRNA level, the loss of SOX2 does not significantly alter expression of the other stemness factors (Figure 3E). These results confirm that the loss of SOX2 is not compensated by the upregulation of other stemness

![Figure 3](image-url)
factors of the core embryonic transcription factor machinery, thereby reinforcing the relevance of the KD strategy used to elucidate the functional role of SOX2.

(2) Loss of SOX2 has an impact on the expression of EMT regulatory factors such as SNAIL and SLUG but not EMT markers. We first assessed the expression of known EMT markers such as E- and N-cadherin by IB analysis in SOX2-scrambled RNAi and siRNA-treated cells. No significant changes in the expression of E- and N-cadherin were observed in SOX2-scrambled RNAi and siRNA-treated PC3 cells (Figure 4A and 4B). IB analysis indeed revealed that SOX2 KD reduces the expression of SNAIL and SLUG (Figure 4C and 4D). These observations suggest that SOX2 does not have any direct effect on the expression of E- or N-cadherin.

(3) SOX2 KD reduces cell migration and tumorsphere formation. First we sought to determine whether SOX2 influences migration. SOX2-scrambled RNAi and siRNA-treated PC3 cells were subjected to wound closure assay. Wound closure was monitored for 18 hours (Figure 5B) and 24 hours (Figure 5C). Scrambled RNAi-treated cells displayed greater migration and wound closure capabilities (Figure 5B and 5C, left panel), with the wound almost closing up at 24 hours (Figure 5C, left panel). A significant decrease in the migration was observed at 18 and 24 hours in PC3 cells transfected with the siRNA (Figure 5B and 5C, right panel). Cells pretreated with mitomycin C ensures that the observed results on cell migration are independent of cell proliferation.

Secondly, we wanted to determine whether SOX2 influences tumorsphere formation. CSCs can form tumorspheres in vitro when plated in limited numbers and under serum-free condition supplemented with growth factors. The cells in a tumorsphere formation assay appear fused together and they are indicative of the cancer stem/progenitor cell population within the culture. Scrambled RNAi and siRNA-treated PC3 cells were subjected to in vitro tumorsphere formation. Scrambled RNAi-treated cells displayed more tumorspheres (Figure 5D, left panel) in comparison with SOX2 siRNA-treated PC3 cells (Figure 5D, right panel) as seen by the formation of spheroids that are fused together to form a solid cluster of cells. A significant decrease in wound closure and tumorsphere formation in PC3 cells KD of SOX2 suggests that SOX2 may play an important role in cell migration, self-renewal, and differentiation (Figure 5A and 5D), which is a part of the EMT process.

3.4 CD44 has a potential role in the expression of SOX2 and migration of PC3 cells

We have previously shown that CD44 increases the invasive property of PC3 cells. Here, we used PC3 cells and PC3 cells stably KD of CD44 (PC3/CD44−) to examine SOX2 expression levels. As shown previously, PC3/CD44− cells were more rounded and less adhesive as compared with PC3 cells (Figure 6A). CD44 KD in PC3 cells resulted in significant downregulation of SOX2 expression (Figure 6B, lane 2). Loss of cell adhesion corresponds with a decreased migration in PC3/CD44− cells (Figure 6C). These observations further highlight the ability of CD44 to influence SOX2 expression, and ultimately regulate the migration. SOX2 may be a potential downstream target of CD44, having an important role in cell migration.

**FIGURE 4** The effect of SOX2 knockdown on the expression of EMT-related factors. An equal amount of protein lysates (40 μg) made from PC3 cells transfected with scrambled RNAi (Sc; lane 1) and siRNA (Si; lane 2) targeting SOX2 were used for immunoblotting analyses (A-E). The N-cadherin blot in (A) was stripped and reprobed with an E-cadherin antibody (B). The SNAIL blot in (C) was stripped twice sequentially and blotted with a SLUG (D) and GAPDH (E) antibody. GAPDH immunoblot demonstrates equal loading of proteins in each lane. Data represent one of the three independent experiments with similar results. EMT, epithelial-mesenchymal transition; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; RNAi, RNA interference; siRNA, small interfering RNA; SOX2, sex-determining region Y (SRY)-box 2.
Androgen/AR axis has been shown to modulate stemness characteristics. PC3 cells are AR− cells. Our aim here is to determine the following: (a) influence of AR on the expression of SOX2 and CD44, and (b) its impact on cell migration. In exploring the AR-CD44-SOX2 axis, we used PC3 cells (negative for AR), and PC3 cells stably expressing AR (PC3/AR+).

We used phase contrast microscopy to assess morphological changes in indicated PCA cell lines.
PC3/AR+ cells are highly adhesive and have an elongated morphology with spindle-like long projections (Figure 7A). Both PCa2b and LNCaP cells are androgen-sensitive cells. PCa2b cells are derived from bone metastasis of African American patient. Phase contrast microscopy analysis demonstrates that PCa2b cells grow in clumps in culture and LNCaP cells have an elongated morphology with spindle-like projections (Figure 7A). AR expression in PC3 cells resulted in reduced levels of CD44 and SOX2 (Figure 7B, lane 2). Notably, the CD44 and SOX2 expression profile in PCa2b and LNCaP cells are very similar to that of PC3/AR+ cells (Figure 7C and 7D). Expression of CD44 and SOX2 are very negligible in these cells (Figure 7D, lanes 2 and 3). Although real-time PCR analysis demonstrates the expression of CD44 at mRNA levels (Figure 7C) in PCa2b, the expression of the CD44 protein is repressed (Figure 7D, lane 2). The direct impact of AR on the inhibition of CD44 protein expression remains unclear and needs further elucidation.

We next examined the relevance of AR-CD44-SOX2 axis on cell migration, using the wound closure assay. PC3 cells and PC3/AR+ cells were subjected to this assay, and wound closure was monitored for 24 hours. PC3/AR+ cells displayed lower migration capabilities as compared with PC3 cells (Figure 7E). These results suggest that AR might impact the cell migration process via modulating CD44 and SOX2 expression.

3.6 KD of AR reduces CD44/SOX2 expression and tumorsphere formation in Pca2B cells

We then proceeded to determine whether KD of AR in PCa2b increases the expression of CD44 and SOX2. We
performed Western blot analysis to confirm KD of AR in PCa2b cells (Figure 8A, lane 2). KD of AR in PCa2b did not upregulate either CD44 or SOX2 proteins (Figure 8B, lane 2). Lysates made from PC3 cells were used as a control (Figure 8B, lane 3). However, KD of AR in PCa2b resulted in decreased ability to form tumorspheres as compared with Scrambled RNAi–treated cells (Figure 8C). Taken together these results suggest that tumorsphere formation occur independently of CD44-SOX2 signaling in PCa2b cells. Overexpression of AR in PC3 cells suppressed CD44 and SOX2 protein levels (Figure 7). AR may have a role in the repression of expression of CD44 in LNCaP and PCa2b cells. One would expect that KD of AR in PCa2b would increase
CD44 and SOX2 expression. However, AR KD did not influence the expression of CD44 and SOX2 proteins although CD44 is expressed at the mRNA level in PCa2b (Figure 7) and LNCaP cells.40 Expression of CD44 seems cell type-specific and possibly depends on the unique physiological and pathological features of the metastatic organs. Together, these results raise several new questions on AR-CD44-SOX2 signaling axis which need further investigation.

4 | DISCUSSION

While AR signaling is critical for the normal development, function, and homeostasis of the prostate gland, it is also thought to play a major role in PCA pathogenesis.41,42 There is accumulating evidence suggesting that the androgen-deprivation therapy initial therapeutic approach aimed at modulating AR signaling, results in the expansion of CSCs.26,43,44 These CSCs which survive through conventional therapies are thought to contribute toward treatment failure and tumor recurrence—clinical challenges associated with PCA therapy. The current study was performed to evaluate the expression of SOX2, OCT4, and NANOG transcription factors in PCA cell lines derived from different metastases, to identify the key stemness factor that determines the “molecular signature” of potential prostate CSCs. Moreover, we also wanted to examine the ability of AR to mediate stemness characteristics of PCA cells. We first screened three cell lines from different metastases (PC3, DU145, and LNCaP) for stemness factor expression. LNCaP cells from lymph node metastasis are positive for AR, hormone-sensitive, and have low metastatic potential. PC3 and DU145 cells from bone and brain metastasis, respectively, are negative for AR, hormone refractory, and have higher metastatic and malignant properties. Normal prostatic epithelial (HPR1) cells were used as controls.31 IB and RT-PCR analyses revealed a markedly increased SOX2 expression at both protein and mRNA levels in PC3 cells. These results are consistent with previous studies by others that indicate
that SOX2 was significantly increased in more malignant cell lines. Moreover, the lack of substantial expression of OCT4 and NANOG in SOX2-expressing PC3 cells suggest that SOX2 could potentially have a novel and significant role in metastasis, independent of its association with other stemness factors. Our strategy to explore the role of SOX2 as a putative marker of prostate CSCs was further driven by the results of our IB analysis of human prostate tissue samples, whereby increased SOX2 expression was observed in TTs as compared with normal tissues. Previous reports corroborate these observations, where SOX2 was found to be associated with tumorigenesis and its overexpression correlated with higher histologic grade and Gleason score. These findings reinforce the clinical relevance of SOX2 expression and its potential role in PCa progression. We decided to use PC3 cell line for all further experimental manipulation as it has the highest CD44 and SOX2 expression, and advanced PCa is known to metastasize to the bones.

Nuclear localization of the SOX2 protein in PC3 cells suggests that it may function as a key transcriptional regulator in these cells. Bearing in mind the accumulating evidence emphasizing the existence of shared molecular characteristics between CSCs and EMT cells, we used a SOX2 KD strategy to elucidate its functional role and potential downstream targets, with regard to EMT and cell migration. The prospect of a potential SOX2-EMT axis would not be surprising, considering that this axis is known to have central roles in the invasion and metastasis of several human cancers. For instance, SOX2 silencing in colorectal cancer cells induced mesenchymal-epithelial transition, a reciprocal process to EMT, with marked changes in the expression of key drivers of EMT such as SNAIL. Consistent with these observations, our analyses indeed revealed reduced expression of EMT regulatory factors SNAIL and SLUG with SOX2 silencing. These results corroborate the decrease in cell migration observed with the SOX2 KD. Our results suggest that SOX2 may have an important role in inducing cell migration, an EMT process, acting through SNAIL and SLUG downstream targets. However, the underlying molecular mechanism by which SOX2 regulates SNAIL and SLUG expression need further elucidation.

CD44 signaling has been shown to modulate the tumor microenvironment and promote EMT-related events through its involvement in processes like cell trafficking, lymph node homing, cell-ECM adhesion, and coordination of cytokine signaling. Strikingly, there is also growing evidence projecting CD44 to be a marker of CSCs in the breast, prostate, pancreas, ovarian, and colorectal cancers. While CD44 has been thought to have a strategic role in PCa progression, the exact mechanism involved is still largely unknown. Hence, in the current study we examined the potential role of CD44, and its relationship with SOX2 using a KD approach. Our studies indeed reveal the ability of CD44 to modulate stemness characteristics of PCa cells, whereby the loss of CD44 reduced expression of SOX2. These observations are in line with reports in breast cancer, where they identified CD44, in particular, its intracellular domain to be critical in influencing the expression of stemness factors and the maintenance of breast CSCs. The morphological changes and a decrease in cell migration witnessed in CD44-silenced cells further validate its role in the EMT process. Intriguingly, our results establish the presence of a reciprocal relationship between CD44 and SOX2. One likely explanation for CD44-regulated SOX2 expression in PC3 cells may be the vision of SOX2 being a potential downstream target of CD44. Additional investigations are required to understand the prospective association between CD44 and SOX2 further.

Suppressing AR signaling remains the primary focus of therapeutic strategies for advanced PCa. However, despite initial favorable response this approach eventually leads to more aggressive disease. With the exact mechanism for treatment failure and tumor recurrence still unclear, some potential explanations put forward...
include the acquisition of CSC phenotype and EMT following selection pressures imposed by androgen-deprivation therapy. The current study was undertaken to determine the influence of AR on the expression of SOX2 and CD44, and to examine the functional consequence of AR-CD44-SOX2 axis. The experimental strategy used involves the expression of AR in PC3 cells that are AR−. Our analyses revealed a significant decrease in the expression of CD44 and SOX2 in response to AR expression in PC3 cells, suggesting that AR signaling may have the potential to reduce stemness characteristics of these cells. Our results are in agreement with others that AR represses the expression of SOX2 and CD44. Strikingly, with the introduction of AR in androgen-independent PC3 cells begin to exhibit characteristics of androgen-dependent PCa2b cells and LNCaP cells, regarding SOX2-CD44 expression profiles. It is vital to note that both PC3 and PCa2b cells are derived from human bone metastasis, with AR being one of the key differentiating factors between them. However, KD of AR in PCa2b cells did not affect the expression of CD44 or SOX2. One explanation for this observation could be that PCa2b cells may preserve both prostate-specific antigen (PSA) and androgen sensitivity in contrast to PC3 cells which do not express AR and PSA. The loss of CD44 expression could be compensated for by the secretion of PSA and androgen sensitivity. Further studies are needed to understand the molecular mechanism involved in the repression of CD44 in AR+ cells or the induction of CD44 expression in AR− cells.

Bone metastatic PCa PC3 cells that are AR− highly express CD44 and SOX2. Expression of CD44 and SOX2 results in the upregulation of transcription factors SNAIL and SLUG, which leads to EMT and hence migration. SNAIL and SLUG have been shown to increase the migration of breast cancer cells. SOX2 KD reduces the levels of SNAIL and SLUG proteins but not cell junction molecules E- or N-cadherin; however decreases cell migration and tumorsphere formation. Our observations in PCa PC3 cells substantiate the possible role of the CD44-SOX2-SNAIL/SLUG axis in migration and tumor progression. Forced expression of AR in PC3 cells results in downregulation of CD44 and SOX2 thereby preventing EMT and migration. Re-expression of AR in PC3 cells may have a potential to reduce the stemness characteristics of these cancer cells (Figure 9). Reduction in stemness characteristics witnessed with AR expression correlated with decreased migration in PC3 cells. Our current studies focus on identifying the molecular mechanisms involved in the regulation of SOX2 by CD44 signaling and the role of CD44-SOX2-SNAIL/SLUG axis in eliciting EMT and migration/tumor progression.

5 | CONCLUSIONS

Taken together, the results of our study would have significant clinical implications regarding enhancing our understanding of prostate CSCs. Here, we show the presence of an AR-CD44-SOX2 axis and recognize SOX2 as a putative CSC marker that can define the “molecular signature” of PCa stem cells. Our observations provide critical knowledge that would enable us to work toward designing a more comprehensive therapeutic approach for advanced PCa. SOX2 could be a potential therapeutic target to impede the progression of SOX2-positive cancer cells or recurrence of androgen-independent PCa.

ACKNOWLEDGMENTS

We thank Dr C. K. Choo (University of Hong Kong, Hong Kong, China) for HPR1 cell line. We thank Dr Joseph Mauban at Confocal Microscopy Core (University of Maryland, Baltimore, MD) for providing technical assistance in using the Zeiss LSM 510 META Confocal Laser Scanning Microscope. Research reported in this publication was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under award number R01 AR066044 to MAC. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

CONFLICTS OF INTEREST

The authors declare that there are no conflicts of interest.

AUTHORS’ CONTRIBUTIONS

DS and LS participated in the design of the study, performed the experiments, analyzed the data, and wrote the manuscript. LS and SM participated in the preparation of lysates from different PCa cells and tumorsphere formation. RBF generated stable PC3 cell line expressing androgen receptor (PC3/AR+). MAC conceived and designed the study, analyzed the data with DS, and was involved in manuscript preparation. All authors read and approved the final manuscript.

ORCID

Meenakshi A. Chellaiah http://orcid.org/0000-0001-6572-1106
REFERENCES

1. Brawer KW. Prostate cancer epidemiology in the United States. World J Urol. 2012;30:195-200.
2. Carlin BI, Andriole GL. The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer. 2000;88:2989-2994.
3. Desai B, Rogers MJ, Chellaiah MA. CD44 as a metastatic principle in prostate cancer. Mol Cancer. 2007;6:18.
4. Attar RM, Takimoto CH, Gottardis MM. Castration-resistant prostate cancer: locking up the molecular escape routes. Clin Cancer Res. 2009;15:3251-3255.
5. Bishop JL, Davies A, Ketola K, Zoubeidi A. Regulation of tumor cell plasticity by the androgen receptor in prostate cancer. Endocr Relat Cancer. 2015;22:R165-R182.
6. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 2003;100:3983-3988.
7. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3:730-737.
8. Klarmann GJ, Hurt EM, Mathews LA, et al. Invasive prostate cancer cells are tumor initiating cells that have a stem cell-like genomic signature. Clin Exp Metastasis. 2009;26:433-446.
9. Kong D, Banerjee S, Ahmad A, et al. Epithelial to mesenchymal transition is mechanistically linked with stem cell signatures in prostate cancer cells. PLOS One. 2010;5:e12445.
10. Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133:704-715.
11. Jeter CR, Liu B, Lu Y, et al. NANOG reprograms prostate cancer cells to castration resistance via dynamically repressing and engaging the AR/FOXA1 signaling axis. Cell Discov. 2016;2:16041.
12. Kregel S, Kiriluk KJ, Rosen AM, et al. Sox2 is an androgen receptor-repressed gene that promotes castration-resistant prostate cancer. PLOS One. 2013;8:e53701.
13. Kregel S, Szmulowitz RZ, Griend DJV. The pluripotency factor Nanog is directly upregulated by the androgen receptor in prostate cancer cells. Prostate. 2014;74:1530-1543.
14. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131:861-872.
15. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126:663-676.
16. Cox JL, Wilder PJ, Desler M, Rizzino A. Elevating SOX2 levels deleteriously affects the growth of medulloblastoma and glioblastoma cells. PLOS ONE. 2012;7:e44087.
17. Leis O, Eguiara A, Lopez-Aribillaga E, et al. Sox2 expression in breast tumours and activation in breast cancer stem cells. Oncogene. 2012;31:1354-1365.
18. Khan M, Hamid A, Adhami V, Lall R, Mukhtar H. Role of epithelial mesenchymal transition in prostate tumorigenesis. Curr Pharm Des. 2015;21:1240-1248.
19. Wu Y, Sarkissyan M, Vadgama JV. Epithelial-Mesenchymal Transition and Breast Cancer. J Clin Med. 2016;5(2):E13.
20. Yu M, Bardia A, Wittner BS, et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science. 2013;339:580-584.
21. Miclizzi DS, Ford HL. Epithelial-mesenchymal transition in development and cancer. Future Oncol. 2009;5:1129-1143.
22. Thiery JP. [Epithelial-mesenchymal transitions in cancer onset and progression]. Bull Acad Natl Med. 2009;193:1969-1978.
23. Thiery JP, Acolique H, Huang RYJ, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139:871-890.
24. Han X, Fang X, Lou X, et al. Silencing SOX2 induced mesenchymal-epithelial transition and its expression predicts liver and lymph node metastasis of CRC patients. PLOS ONE. 2012;7:e41335.
25. Herreros-Villanueva M, Zhang JS, Koenig A, et al. SOX2 promotes dedifferentiation and imparts stem cell-like features to pancreatic cancer cells. Oncogenesis. 2013a;2:e61-e61.
26. Sun Y, Wang BE, Leong KG, et al. Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy. Cancer Res. 2012;72:527-536.
27. Ponta H, Sherman L, Herrlich PA. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol. 2003;4:33-45.
28. Senbanjo LT, Chellaiah MA. CD44: a multifunctional cell surface adhesion receptor is a regulator of progression and metastasis of cancer cells. Front Cell Dev Biol. 2017;5:18.
29. Cho Y, Lee HW, Kang HG, Kim HY, Kim SJ, Chun KH. Cleaved CD44 intracellular domain supports activation of stemness factors and promotes tumorigenesis of breast cancer. Oncotarget. 2015;6:8709-8721.
30. Gupta A, Cao W, Chellaiah MA. Integrin αvβ3 and CD44 pathways in metastatic prostate cancer cells support osteoclastogenesis via RUNX2/Smad5/RANKL signaling axis. Mol Cancer. 2012;11:66.
31. Choo CK, Ling MT, Chan KW, et al. Immortalization of human prostate epithelial cells by HPV 16 E6/E7 open reading frames. Prostate. 1999;40:150-158.
32. Navone NM, Olive M, Ozen M, et al. Establishment of two human prostate cancer cell lines derived from a single bone metastasis. Clin Cancer Res. 1997;3:2493-2500.
33. Desai B, Ma T, Zhu J, Chellaiah MA. Characterization of the expression of variant and standard CD44 in prostate cancer metastasis. Clin Cancer Res. 2009;15:3255-3259.
34. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C (T)) Method. Methods. 2001;25:402-408.
35. Chellaiah M, Hruska K. Osteopontin stimulates gelsolin associated phosphoinositide levels and PtdIns 3-hydroxyl kinase. Mol Biol Cell. 1996;7:743-753.
36. Johnson S, Chen H, Lo PK. In vitro tumorsphere formation assays. Bio Protoc. 2013;3(3):e325.
37. Shaheen S, Nateri AS. Spheroid formation (colonosphere) assay for in vitro assessment and expansion of stem cells in colon cancer. Stem Cell Rev. 2016;12:492-499.
38. Fujimura T, Takahashi S, Urano T, et al. Expression of androgen and estrogen signaling components and stem cell markers to predict cancer progression and cancer-specific survival in patients with metastatic prostate cancer. Clin Cancer Res. 2014;20:4625-4635.
39. Berger R, Febbo PG, Majumder PK, et al. Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells. Cancer Res. 2004;64:8867-8875.

40. Stevens JW, Palechek PL, Griebling TL, Midura RJ, Rokhlin OW, Cohen MB. Expression of CD44 isoforms in human prostate tumor cell lines. Prostate. 1996;28:153-161.

41. Coffey DS, Isaacs JT. Control of prostate growth. Urology. 1981;17:17-24.

42. Balk SP. Androgen receptor as a target in androgen-independent prostate cancer. Urology. 2002;60:132-138.

43. Chen CL, Mahalingam D, Osmulski P, et al. Single-cell analysis of circulating tumor cells identifies cumulative expression patterns of EMT-related genes in metastatic prostate cancer. Prostate. 2013;73:813-826.

44. Armstrong AJ, Marengo MS, Oltean S, et al. Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. Mol Cancer Res. 2011;9:997-1007.

45. Jia X, Li X, Xu Y, et al. SOX2 promotes tumorigenesis and increases the anti-apoptotic property of human prostate cancer cell. J Mol Cell Biol. 2011;3:230-238.

46. Li X, Xu Y, Chen Y, et al. SOX2 promotes tumor metastasis by stimulating epithelial-to-mesenchymal transition via regulation of WNT/beta-catenin signal network. Cancer Lett. 2013;336:379-389.

47. Shou J, Zhang Q, Wang S, Zhang D. The prognosis of different distant metastases pattern in prostate cancer: a population based retrospective study. Prostate. 2018;78(7):491-497.

48. Butler AM, Cetin K, Hernandez RK, et al. Treatment dynamics of bone-targeting agents among men with bone metastases from prostate cancer in the United States. Pharmacoepidemiol Drug Safety. 2018;27:229-238.

49. Herreros-Villanueva M, Zhang JS, Koenig A, et al. SOX2 promotes dedifferentiation and imparts stem cell-like features to pancreatic cancer cells. Oncogenesis. 2013b;2:e61-e61.

50. Rhim AD, Mirek ET, Aiello NM, et al. EMT and dissemination precede pancreatic tumor formation. Cell. 2012;148:349-361.

51. Misra S, Heldin P, Hascall VC, et al. Hyaluronan-CD44 interactions as potential targets for cancer therapy. FEBS J. 2011;278:1429-1443.

52. Chamnue T, Ontong P, Kimata K, Itano N. Key roles of hyaluronan and its CD44 receptor in the stemness and survival of cancer stem cells. Front Oncol. 2015;5:180.

53. Gotte M, Yip GW. Heparanase, hyaluronan, and CD44 in cancers: a breast carcinoma perspective. Cancer Res. 2006;66:10233-10237.

54. Yeung F, Law WK, Yeh CH, et al. Regulation of human osteocalcin promoter in hormone-independent human prostate cancer cells. J Biol Chem. 2002;277:2468-2476.

55. Dhasarathy A, Phadke D, Mav D, Shah RR, Wade PA. The transcription factors Snail and Slug activate the transforming growth factor-beta signaling pathway in breast cancer. PLOS One. 2011;6:e26514.

How to cite this article: Srinivasan D, Senbanjo L, Majumdar S, Franklin RB, Chellaiah MA. Androgen receptor expression reduces stemness characteristics of prostate cancer cells (PC3) by repression of CD44 and SOX2. J Cell Biochem. 2019;120:2413-2428. https://doi.org/10.1002/jcb.27573